论文部分内容阅读
目的探讨血浆胱抑素C(PcyC)和高敏C反应蛋白(hs-CRP)对冠心病预防及治疗的临床价值。方法选择冠心病患者36例,设同期因胸闷胸痛症状入院经冠状动脉造影排外冠心病的患者34例作为对照组。测定所有患者PcyC和hs-CRP水平。对所有患者随访6个月,记录其心血管不良事件的发生情况。结果 UAP组PcyC水平显著高于SAP组和对照组,但低于AMI组;而UAP组和AMI组hs-CRP浓度较SAP组和对照组显著增高。结论 PcyC参与了冠心病的发病过程,PcyC是冠心病及其不良预后的一个重要的预测因子。
Objective To investigate the clinical value of plasma cystatin C (PcyC) and high-sensitivity C-reactive protein (hs-CRP) in the prevention and treatment of coronary heart disease. Methods Thirty-six patients with coronary heart disease (CHD) were enrolled in this study. 34 patients with CHD due to chest pain and chest pain during the same period were selected as control group. All patients were measured PcyC and hs-CRP levels. All patients were followed up for 6 months and the occurrence of cardiovascular adverse events was recorded. Results The level of PcyC in UAP group was significantly higher than that in SAP group and control group, but lower than that in AMI group. The concentration of hs-CRP in UAP group and AMI group was significantly higher than that in SAP group and control group. Conclusion PcyC participates in the pathogenesis of coronary heart disease. PcyC is an important predictor of coronary heart disease and its adverse prognosis.